MA34058B1 - Formes de rifaximine, et leurs utilisations - Google Patents

Formes de rifaximine, et leurs utilisations

Info

Publication number
MA34058B1
MA34058B1 MA35196A MA35196A MA34058B1 MA 34058 B1 MA34058 B1 MA 34058B1 MA 35196 A MA35196 A MA 35196A MA 35196 A MA35196 A MA 35196A MA 34058 B1 MA34058 B1 MA 34058B1
Authority
MA
Morocco
Prior art keywords
forms
rifaximine
pharmaceutical
rifaximin
relates
Prior art date
Application number
MA35196A
Other languages
Arabic (ar)
English (en)
Inventor
Karen S Gushurst
Donglai Yang
Petinka Vlahova
Jeffrey S Stults
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MA34058B1 publication Critical patent/MA34058B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des formes polymorphiques de rifaximine, leur utilisation dans des préparations médicamenteuses, et des traitements thérapeutiques les utilisant.
MA35196A 2010-02-19 2011-02-16 Formes de rifaximine, et leurs utilisations MA34058B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (fr) 2010-02-19 2011-02-16 Formes de rifaximine, et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34058B1 true MA34058B1 (fr) 2013-03-05

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35196A MA34058B1 (fr) 2010-02-19 2011-02-16 Formes de rifaximine, et leurs utilisations

Country Status (21)

Country Link
US (5) US8486956B2 (fr)
EP (1) EP2536734B1 (fr)
JP (2) JP2013520427A (fr)
KR (1) KR20120140244A (fr)
CN (2) CN105254647A (fr)
AU (3) AU2011218258B2 (fr)
BR (1) BR112012020863A2 (fr)
CA (1) CA2790332A1 (fr)
CR (1) CR20120449A (fr)
EA (1) EA201270722A1 (fr)
GE (2) GEP201706745B (fr)
IL (1) IL221299A (fr)
MA (1) MA34058B1 (fr)
MX (1) MX353827B (fr)
MY (1) MY158992A (fr)
NZ (1) NZ601670A (fr)
PH (1) PH12012501623A1 (fr)
SG (1) SG183188A1 (fr)
TN (1) TN2012000414A1 (fr)
WO (1) WO2011103120A1 (fr)
ZA (1) ZA201206227B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
GEP20135898B (en) 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
WO2011061748A1 (fr) * 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
MX2012013945A (es) * 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
PH12013500082B1 (en) * 2010-07-12 2019-06-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
CN103221032A (zh) * 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
MX350448B (es) 2011-02-11 2017-09-07 Salix Pharmaceuticals Ltd Formas de rifaximina y usos de las mismas.
EP2705042A1 (fr) * 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Solvate de diméthylformamide rifaximine
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
EP2773205B1 (fr) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximine pour le traitement du syndrome du côlon irritable avec diarrhée
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (fr) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Formes polymorphes de rifaximine
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EA032705B1 (ru) 2013-04-12 2019-07-31 Альфасигма С.П.А. Способ лечения или предупреждения энтеропатии
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015171493A1 (fr) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Microbiote du syndrome du côlon irritable et utilisations associées
DK3546464T3 (da) 2014-05-12 2020-07-27 Alfasigma Spa Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
WO2016204474A2 (fr) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 Composition vétérinaire pour le traitement de l'entérite chez les animaux contenant des formes cristallines de rifaximine
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ，インコーポレーテッド リファキシミンの固体分散体の形態
JP7825575B2 (ja) 2020-06-26 2026-03-06 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
EP1248869A2 (fr) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
WO2006012470A1 (fr) * 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Derives de rifamycine pour traiter des infections microbiennes
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2008035109A1 (fr) 2006-09-22 2008-03-27 Cipla Limited Rifaximine
WO2008085484A2 (fr) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Procédé de traitement de l'affection abdominale inflammatoire
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (fr) 2007-07-06 2009-01-15 Lupin Limited Compositions pharmaceutiques de rifaximine
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
GEP20135898B (en) 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage
WO2009137672A1 (fr) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
AU2009292615B2 (en) 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
GEP201706693B (en) 2009-10-27 2017-07-10 Lupin Ltd Solid dispersion of rifaximin
EP2401282B2 (fr) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Procédés pour la production de rifaximine amorphe
MX2012013945A (es) * 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
MX350448B (es) * 2011-02-11 2017-09-07 Salix Pharmaceuticals Ltd Formas de rifaximina y usos de las mismas.

Also Published As

Publication number Publication date
US20140179916A1 (en) 2014-06-26
TN2012000414A1 (en) 2014-01-30
US20160200738A1 (en) 2016-07-14
AU2011218258A1 (en) 2012-08-30
CA2790332A1 (fr) 2011-08-25
IL221299A0 (en) 2012-10-31
MX353827B (es) 2018-01-31
US20120316334A1 (en) 2012-12-13
US9034892B2 (en) 2015-05-19
US20100174064A1 (en) 2010-07-08
CR20120449A (es) 2012-11-29
US8486956B2 (en) 2013-07-16
WO2011103120A1 (fr) 2011-08-25
MX2012009576A (es) 2012-12-05
PH12012501623A1 (en) 2012-10-22
US8569326B2 (en) 2013-10-29
CN105254647A (zh) 2016-01-20
HK1179608A1 (zh) 2013-10-04
AU2016269529A1 (en) 2017-01-05
GEP20156230B (en) 2015-01-26
EA201270722A1 (ru) 2013-03-29
AU2011218258B2 (en) 2015-11-05
EP2536734A1 (fr) 2012-12-26
MY158992A (en) 2016-11-30
SG183188A1 (en) 2012-09-27
US9273066B2 (en) 2016-03-01
EP2536734B1 (fr) 2016-08-31
CN102834398A (zh) 2012-12-19
JP2013520427A (ja) 2013-06-06
AU2014246594A1 (en) 2014-10-30
GEP201706745B (en) 2017-10-10
EP2536734A4 (fr) 2013-06-26
IL221299A (en) 2017-11-30
AU2014246594B2 (en) 2016-09-15
KR20120140244A (ko) 2012-12-28
JP2016094416A (ja) 2016-05-26
AU2016269529B2 (en) 2018-06-07
BR112012020863A2 (pt) 2016-06-21
US20140141081A1 (en) 2014-05-22
ZA201206227B (en) 2018-12-19
US9546183B2 (en) 2017-01-17
NZ601670A (en) 2014-11-28

Similar Documents

Publication Publication Date Title
MA34058B1 (fr) Formes de rifaximine, et leurs utilisations
HUS2200034I1 (hu) Glikokonjugációs eljárások és kompozíciók
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
BR112015008245A2 (pt) composições poliméricas de tratamento.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
DK2723615T3 (da) Ulykkesbekæmpelsessystem og køretøj, der indbefatter ulykkesbekæmpelsessystemet
EA201290642A1 (ru) Соединения и способы
EP2844637A4 (fr) Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
IN2012DN06714A (fr)
BR112013016037A2 (pt) composição em gel.
EP2654422A4 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
FR2993565B1 (fr) Composes fluorescents de type thienyldipyrromethene bores et leurs utilisations.
UY34817A (es) Tienopirimidinas
EP2918681A4 (fr) Gène de la fertilité et utilisations associées
EA201590962A1 (ru) Новые соединения
EP2672970A4 (fr) Formes de rifaximine et leurs utilisations
BR112013012450A2 (pt) composições, métodos de detecção e kits
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
BR112015003829A2 (pt) novos copolímeros anfifílicos de enxerto
EP2691396A4 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
EP2926712A4 (fr) Système d'insufflation
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
BR112015005627A2 (pt) composto, composição farmacêutica, uso de composto, método de tratamento e invenção.